Advertisement

Comparison of sodium fluorescein and intraoperative ultrasonography in brain tumor resection

      Highlights

      • SF and IOUS are two widely used intraoperative imaging modalities in neurosurgery.
      • In direct comparison to IOUS, SF may have superior efficacy in tumor resection.
      • Both SF and IOUS demonstrate high efficacy in tumor resection.
      • Their combined use, recognizing strengths and weaknesses, may be most efficacious.

      Abstract

      Various intraoperative neuroimaging modalities are available to the neurosurgeon during brain tumor surgery. There remains no consensus on which modalities are superior. This retrospective, single-center cohort study directly compares sodium fluorescein (SF) and intraoperative ultrasonography (IOUS) as intraoperative imaging modalities in a sample of patients with glioblastoma isocitrate dehydrogenase 1 wildtype (GBM). Adult patients with GBM who underwent surgical resection using SF or IOUS guidance between 2010 and 2020 were included. Primary outcomes included extent of resection (EOR), post-operative residual tumor volume, gross total resection (GTR) rate, false negative assessments, and the incidence of new post-operative neurologic deficits. Additionally, pre-and post-test probabilities were calculated to assess each modality’s ability to identify residual tumor. 98 patients met inclusion criteria (34 SF and 64 IOUS). Mean EOR was significantly higher for SF (94 ± 11 %) when compared to IOUS (87 ± 20 %; p = 0.032). Mean post-operative residual tumor was significantly higher for IOUS (197 ± 358 mm2) when compared to SF (81 ± 161mm2; p = 0.038). GTR was more frequent with SF (62 % vs 46 %, p = 0.12). False negative assessments for residual tumor were more common with IOUS (22 % vs 15 %, p = 0.53). One patient in each group suffered a new neurologic deficit post-operatively (p = 0.58). Sensitivity, specificity, positive predictive value, and negative predictive value were 62 %, 100 %, 100 %, and 81 % for SF and 59 %, 100 %, 100 %, and 67 % for IOUS, respectively. Taken together, SF may be superior to IOUS in maximizing EOR in patients with GBM, however, both modalities appear to have good efficacy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bayer S.
        • Maier A.
        • Ostermeier M.
        • Fahrig R.
        Intraoperative Imaging Modalities and Compensation for Brain Shift in Tumor Resection Surgery.
        Int J Biomed Imaging. 2017; 2017: 6028645https://doi.org/10.1155/2017/6028645
        • Belykh E.
        • Martirosyan N.L.
        • Yagmurlu K.
        • Miller E.J.
        • Eschbacher J.M.
        • Izadyyazdanabadi M.
        • et al.
        Intraoperative Fluorescence Imaging for Personalized Brain Tumor Resection: Current State and Future Directions.
        Front Surg. 2016; 3https://doi.org/10.3389/fsurg.2016.00055
      1. Jenkinson MD, Barone DG, Bryant A, et al. Intraoperative imaging technology to maximise extent of resection for glioma. The Cochrane database of systematic reviews. Jan 22 2018;1(1):Cd012788. 10.1002/14651858.CD012788.pub2.

        • Brown T.J.
        • Brennan M.C.
        • Li M.
        • Church E.W.
        • Brandmeir N.J.
        • Rakszawski K.L.
        • et al.
        Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis.
        JAMA Oncol. 2016; 2: 1460
        • Karschnia P.
        • Vogelbaum M.A.
        • van den Bent M.
        • Cahill D.P.
        • Bello L.
        • Narita Y.
        • et al.
        Evidence-based recommendations on categories for extent of resection in diffuse glioma.
        Eur J Cancer. 2021; 149: 23-33
        • D'Amico R.S.
        • Englander Z.K.
        • Canoll P.
        • Bruce J.N.
        Extent of Resection in Glioma-A Review of the Cutting Edge.
        World neurosurgery. Jul 2017; 103: 538-549https://doi.org/10.1016/j.wneu.2017.04.041
        • Wykes V.
        • Zisakis A.
        • Irimia M.
        • Ughratdar I.
        • Sawlani V.
        • Watts C.
        Importance and Evidence of Extent of Resection in Glioblastoma.
        J Neurol Surg A Cent Eur Neurosurg. Jan 2021; 82: 75-86https://doi.org/10.1055/s-0040-1701635
        • Cahill D.P.
        Extent of Resection of Glioblastoma: A Critical Evaluation in the Molecular Era.
        Neurosurg Clin N Am. Jan 2021; 32: 23-29https://doi.org/10.1016/j.nec.2020.09.006
        • Molinaro A.M.
        • Hervey-Jumper S.
        • Morshed R.A.
        • Young J.
        • Han S.J.
        • Chunduru P.
        • et al.
        Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
        JAMA Oncol. 2020; 6: 495
        • Ng P.R.
        • Choi B.D.
        • Aghi M.K.
        • Nahed B.V.
        Surgical advances in the management of brain metastases.
        Neurooncol Adv. Nov 2021; 3: v4-v15https://doi.org/10.1093/noajnl/vdab130
        • Rivera M.
        • Norman S.
        • Sehgal R.
        • Juthani R.
        Updates on Surgical Management and Advances for Brain Tumors.
        Curr Oncol Rep. 2021; 23
        • Eatz T.A.
        • Eichberg D.G.
        • Lu V.M.
        • Di L.
        • Komotar R.J.
        • Ivan M.E.
        Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review.
        J Neurooncol. Jan 2022; 156: 233-256https://doi.org/10.1007/s11060-021-03901-9
        • Cavallo C.
        • De Laurentis C.
        • Vetrano I.G.
        • Falco J.
        • Broggi M.
        • Schiariti M.
        • et al.
        The utilization of fluorescein in brain tumor surgery: a systematic review.
        J Neurosurg Sci. 2018; 62
        • Noh T.
        • Mustroph M.
        • Golby A.J.
        Intraoperative Imaging for High-Grade Glioma Surgery.
        Neurosurg Clin N Am. Jan 2021; 32: 47-54https://doi.org/10.1016/j.nec.2020.09.003
        • Rogers C.M.
        • Jones P.S.
        • Weinberg J.S.
        Intraoperative MRI for Brain Tumors.
        J Neurooncol. Feb 2021; 151: 479-490https://doi.org/10.1007/s11060-020-03667-6
        • Dixon L.
        • Lim A.
        • Grech-Sollars M.
        • Nandi D.
        • Camp S.
        Intraoperative ultrasound in brain tumor surgery: A review and implementation guide.
        Neurosurg Rev. 2022; 45: 2503-2515
        • Manoharan R.
        • Parkinson J.
        Sodium Fluorescein in Brain Tumor Surgery: Assessing Relative Fluorescence Intensity at Tumor Margins.
        Asian J Neurosurg Jan-Mar. 2020; 15: 88-93https://doi.org/10.4103/ajns.AJNS_221_19
        • Sastry R.
        • Bi W.L.
        • Pieper S.
        • Frisken S.
        • Kapur T.
        • Wells W.
        • et al.
        Applications of Ultrasound in the Resection of Brain Tumors.
        Journal of neuroimaging : official journal of the American Society of Neuroimaging. 2017; 27: 5-15
      2. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncology. Aug 2 2021;23(8):1231-1251. 10.1093/neuonc/noab106.

      3. Mazurek M, Kulesza B, Stoma F, Osuchowski J, Mańdziuk S, Rola R. Characteristics of Fluorescent Intraoperative Dyes Helpful in Gross Total Resection of High-Grade Gliomas-A Systematic Review. Diagnostics (Basel). Dec 16 2020;10(12) 10.3390/diagnostics10121100.

        • Yang D.
        Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria.
        Neurooncol Pract. Mar 2016; 3: 59-67https://doi.org/10.1093/nop/npv023